http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2233146-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate | 2002-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87705f666717b442b9e8c62e2b5fdf58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d95fa2c902dca65da5fb3a6b56071be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d8f96fa642925141467765818d54e43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a32822ca0db54a974514a98c077cbb27 |
| publicationDate | 2004-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2233146-C2 |
| titleOfInvention | Method for treating cystic filtration pads |
| abstract | FIELD: medicine, ophthalmology. n SUBSTANCE: the present innovation deals with treating cystic filtration pads after antiglaucomatous operations. One should introduce a photosensitizer as porphyrins of chlorine row into pad's cavity. Then one should affect with coagulating radiation of argon laser at 488-514 nm wave length, 0.3-0.5 W radiation power of argon laser, 50-500 mcm diameter of focal spot and 0.15-0.2 sec exposure. The method enables to normalize intraocular pressure, decrease the development of inflammatory complications due to decreased thermal impact onto ocular tissues. n EFFECT: higher efficiency of therapy. n 2 cl, 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2458657-C1 |
| priorityDate | 2002-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.